ArticlePediatric research2026
Dose-dependent effects of Alveofact with and without steroids on neutrophil extracellular traps in neonatal respiratory distress syndrome.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06367881 (Assessment Of Dose-Dependent Immunomodulatory Effect Of Intratracheal Alveofact With Or Without Local Steroids In Respiratory Distress Syndrome Of Preterm Neonates), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment Of Dose-Dependent Immunomodulatory Effect Of Intratracheal Alveofact With Or Without Local Steroids In Respiratory Distress Syndrome Of Preterm Neonates
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeutrophil extracellular traps (NETs), peptidyl arginine deiminase 4 (PAD4), and oxidative stress play central roles in neonatal respiratory distress syndrome (RDS). This study investigated whether exogenous surfactant (Alveofact) combined with intratracheal budesonide modulates these pathways.
methodsSixty preterm neonates with RDS were randomized into four groups to receive Alveofact 50 mg/kg or 100 mg/kg, with or without budesonide 0.25 mg/kg. Tracheal aspirates (TA) and blood samples were obtained at baseline and 24 h post-treatment, and an additional blood sample was obtained at 48 hours. NETs were measured by ELISA, oxidative stress by malondialdehyde (MDA) assay, and PAD4 expression by qPCR. Clinical outcomes, including hospital stay and mortality, were recorded.
resultsThe combination of Alveofact 100 mg/kg with budesonide significantly reduced NETs and secretory Immunoglobin A (sIgA) in TA, plasma NETs, MDA, and PAD4 expression compared with other treatment groups (p < 0.05). Plasma and TA NETs levels were strongly correlated across time points. No significant differences were observed in hospital stay, mortality, or complications among groups.
conclusionA combination of 100 mg/kg Alveofact with budesonide effectively attenuates neutrophil-driven inflammation and oxidative stress in neonatal RDS. The study was registered on the Clinical Trial Registration Site (ID: NCT06367881, first submitted 2024-04-07). CLINICAL
trial registrationhttps://www. CLINICALTRIALS: gov/study/NCT06367881?term=NCT06367881&rank=1 IMPACT: High-dose Alveofact + budesonide lowers NETs, PAD4, and oxidative stress. Plasma NETs strongly correlate with normalized tracheal aspirates NETs. First trial to test surfactant-steroid effects on neutrophil pathways in RDS. Therapy reduces neutrophil-mediated inflammation in preterm neonates. Plasma NETs may serve as a minimally invasive biomarker for RDS monitoring.
Identifiers
41872545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.